|
Relative signal values of inflammatory genes significantly affected by IL-1 and/or glucosamine |
||||
| Gene |
Treatment group |
|||
| No glucosamine, no IL-1 |
Glucosamine, no IL-1 |
IL-1, no glucosamine |
Glucosamine with IL-1 |
|
|
|
||||
| Arginosuccinate synthetase |
6.3 |
19.4 |
2247.3 |
267.2 |
| β-Nerve growth factor |
16.1 |
21.6 |
196.2 |
13.0 |
| Bone morphogenetic protein 2 |
42.7 |
57.7 |
375.4 |
100.2 |
| Bone morphogenetic protein 4 |
494.9 |
77.3 |
147.7 |
68.2 |
| Bone morphogenetic protein 6 |
60.9 |
13.9 |
435.9 |
85.9 |
| Bone morphogenetic protein 7 |
0.9 |
5.8 |
76.2 |
8.2 |
| CCL3 (MIP-1a) |
- |
0.1 |
690.7 |
2.6 |
| CCL5 (RANTES) |
2.1 |
2.7 |
310.1 |
8.1 |
| CCL7 (MCP-3) |
32.2 |
69.4 |
3076.0 |
662.8 |
| CCL22 (MDC) |
0.3 |
0.6 |
47.2 |
5.4 |
| Cdc42 GTPase inhibiting protein |
105.0 |
116.5 |
189.4 |
124.4 |
| Colony-stimulating factor 1 |
126.9 |
51.1 |
307.8 |
140.8 |
| Colony-stimulating factor 2 |
- |
20.1 |
1210.7 |
17.6 |
| Colony-stimulating factor 3 |
- |
6.0 |
1253.7 |
6.5 |
| CXCL1 (GROa) |
168.2 |
36.6 |
1730.6 |
496.2 |
| CXCL2 (GROb) |
- |
37.5 |
2988.2 |
92.4 |
| CXCL5 (LIX) |
2.0 |
2.4 |
441.3 |
16.2 |
| CXCL10 (IP-10) |
10.7 |
8.1 |
74.4 |
15.6 |
| CXCL11 (I-TAC) |
- |
- |
110.2 |
3.4 |
| CXCL12 (SDF-a/b) |
122.8 |
5.9 |
88.7 |
10.9 |
| Cyclooxygenase 1 |
184.0 |
593.4 |
192.2 |
493.1 |
| Cyclooxygenase 2 |
61.9 |
117.0 |
3493.9 |
405.5 |
| Cysteine knot superfamily 1 (bone morphogenetic protein antagonist 1) |
460.4 |
308.6 |
2174.9 |
732.7 |
| Cytokine-induced neutrophil chemoattractant-2 |
15.2 |
54.4 |
3466.1 |
624.2 |
| Dual-specificity phosphatase 6 |
179.9 |
88.9 |
658.7 |
109.9 |
| Endothelial PAS domain protein 1 |
69.9 |
38.0 |
208.9 |
52.2 |
| Fibroblast growth factor 7 |
1294.4 |
1078.9 |
1318.9 |
1745.9 |
| Fibroblast growth factor 9 |
12.0 |
29.5 |
155.7 |
26.7 |
| Fibroblast growth factor receptor 1 |
605.2 |
653.7 |
329.3 |
638.5 |
| I-κBα |
126.9 |
81.7 |
1108.4 |
399.0 |
| I-κBβ |
55.6 |
96.6 |
298.2 |
139.2 |
| I-κBγ (NF-κB p105 subunit) |
124.2 |
107.9 |
471.2 |
163.6 |
| Insulin-like growth factor binding protein 3 |
81.6 |
7.4 |
249.9 |
10.4 |
| Insulin-like growth factor binding protein 5 |
174.4 |
569.0 |
737.8 |
229.5 |
| IL-1α |
1.5 |
3.2 |
175.3 |
4.5 |
| IL-1β |
- |
2.4 |
119.4 |
2.7 |
| IL-6 |
57.3 |
53.4 |
1717.8 |
159.0 |
| IL-11 |
- |
- |
124.4 |
- |
| IL-13 receptor, α 1 |
174.8 |
144.5 |
337.4 |
148.0 |
| IL-23α subunit p19 |
- |
- |
766.5 |
- |
| Janus kinase 2 |
89.7 |
102.9 |
251.0 |
128.7 |
| JunB proto oncogene |
129.5 |
89.0 |
377.8 |
148.4 |
| Mitogen-activated protein kinase phosphatase (CPG21) |
19.1 |
47.5 |
300.2 |
52.3 |
| Nitric oxide synthase 2 |
0.1 |
2.1 |
1033.9 |
66.1 |
| Ornithine aminotransferase |
1080.5 |
1125.0 |
868.6 |
1059.1 |
| Ornithine decarboxylase antizyme inhibitor |
322.1 |
239.4 |
336.9 |
186.6 |
| Phospholipase A2, group 2A |
175.5 |
44.7 |
2085.9 |
358.0 |
| Phospholipase A2, group 4A |
269.9 |
303.2 |
668.2 |
339.7 |
| Phospholipase A2, group 5 |
44.0 |
18.2 |
260.7 |
66.7 |
| Platelet-derived growth factor A |
439.8 |
492.9 |
745.9 |
597.5 |
| Prostaglandin E2 synthase |
32.8 |
46.9 |
3845.8 |
183.7 |
| Pyrroline-5-carboxylate |
602.5 |
643.8 |
348.3 |
609.3 |
| Rel-B |
31.6 |
28.7 |
186.2 |
71.5 |
| Small inducible cytokine A2 |
221.4 |
711.0 |
4835.8 |
2945.5 |
| Small inducible cytokine A20 |
26.9 |
137.8 |
4206.1 |
1609.7 |
| Solute carrier family 7 (cationic amino acid transporter), member 8 |
8.1 |
19.4 |
560.3 |
21.7 |
| Sox-4 |
533.0 |
460.8 |
248.5 |
572.2 |
| TNF-induced protein 6 |
119.8 |
49.3 |
262.3 |
71.1 |
Gouze et al. Arthritis Research & Therapy 2006 8:R173 doi:10.1186/ar2082 |
||||